GENMAB A/S -SP ADR (GMAB)
US3723032062 - ADR
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 565 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make GMAB a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
GMAB had positive earnings in the past year.
In the past year GMAB had a positive cash flow from operations.
GMAB had positive earnings in each of the past 5 years.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
GMAB has a Return On Assets of 14.25%. This is amongst the best in the industry. GMAB outperforms 97.69% of its industry peers.
GMAB's Return On Equity of 17.77% is amongst the best of the industry. GMAB outperforms 96.98% of its industry peers.
With an excellent Return On Invested Capital value of 13.65%, GMAB belongs to the best of the industry, outperforming 96.80% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 13.59%.
The last Return On Invested Capital (13.65%) for GMAB is above the 3 year average (13.32%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.25% | ||
| ROE | 17.77% | ||
| ROIC | 13.65% |
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
1.3 Margins
GMAB has a Profit Margin of 29.01%. This is amongst the best in the industry. GMAB outperforms 98.22% of its industry peers.
In the last couple of years the Profit Margin of GMAB has declined.
The Operating Margin of GMAB (31.65%) is better than 99.11% of its industry peers.
In the last couple of years the Operating Margin of GMAB has declined.
Looking at the Gross Margin, with a value of 96.83%, GMAB belongs to the top of the industry, outperforming 96.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.65% | ||
| PM (TTM) | 29.01% | ||
| GM | 96.83% |
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
GMAB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, GMAB has more shares outstanding
Compared to 1 year ago, GMAB has a worse debt to assets ratio.
2.2 Solvency
GMAB has an Altman-Z score of 9.53. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
GMAB has a better Altman-Z score (9.53) than 85.59% of its industry peers.
The Debt to FCF ratio of GMAB is 0.16, which is an excellent value as it means it would take GMAB, only 0.16 years of fcf income to pay off all of its debts.
GMAB's Debt to FCF ratio of 0.16 is amongst the best of the industry. GMAB outperforms 97.33% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that GMAB is not too dependend on debt financing.
GMAB's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. GMAB outperforms 41.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.16 | ||
| Altman-Z | 9.53 |
ROIC/WACC2.04
WACC6.68%
2.3 Liquidity
A Current Ratio of 5.03 indicates that GMAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.03, GMAB is in line with its industry, outperforming 54.09% of the companies in the same industry.
GMAB has a Quick Ratio of 5.02. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.02, GMAB perfoms like the industry average, outperforming 55.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 5.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.53% over the past year.
Measured over the past years, GMAB shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.70% on average per year.
GMAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.57%.
The Revenue has been growing by 40.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.53%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS Q2Q%-38.72%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Sales Q2Q%16.78%
3.2 Future
Based on estimates for the next years, GMAB will show a very strong growth in Earnings Per Share. The EPS will grow by 23.29% on average per year.
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 17.88% on average per year.
EPS Next Y30.57%
EPS Next 2Y22.38%
EPS Next 3Y23.55%
EPS Next 5Y23.29%
Revenue Next Year28.56%
Revenue Next 2Y22.38%
Revenue Next 3Y19.9%
Revenue Next 5Y17.88%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.10, the valuation of GMAB can be described as rather expensive.
95.73% of the companies in the same industry are more expensive than GMAB, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.54. GMAB is valued slightly cheaper when compared to this.
GMAB is valuated correctly with a Price/Forward Earnings ratio of 14.56.
96.62% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.1 | ||
| Fwd PE | 14.56 |
4.2 Price Multiples
97.51% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaper than 97.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.35 | ||
| EV/EBITDA | 10.67 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of GMAB may justify a higher PE ratio.
GMAB's earnings are expected to grow with 23.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.66
PEG (5Y)0.89
EPS Next 2Y22.38%
EPS Next 3Y23.55%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENMAB A/S -SP ADR
NASDAQ:GMAB (12/26/2024, 3:07:10 PM)
20.5
+0.03 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.28%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.02B
Analysts75
Price Target153.56 (649.07%)
Short Float %3.19%
Short Ratio1.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.35%
Min EPS beat(2)3.45%
Max EPS beat(2)67.24%
EPS beat(4)3
Avg EPS beat(4)16.67%
Min EPS beat(4)-58.69%
Max EPS beat(4)67.24%
EPS beat(8)5
Avg EPS beat(8)8.97%
EPS beat(12)9
Avg EPS beat(12)23.79%
EPS beat(16)12
Avg EPS beat(16)39.43%
Revenue beat(2)2
Avg Revenue beat(2)5.35%
Min Revenue beat(2)4.57%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)3.6%
Min Revenue beat(4)0.19%
Max Revenue beat(4)6.12%
Revenue beat(8)8
Avg Revenue beat(8)4.78%
Revenue beat(12)12
Avg Revenue beat(12)4.08%
Revenue beat(16)16
Avg Revenue beat(16)6.35%
PT rev (1m)0%
PT rev (3m)6.55%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-2.44%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)2.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.1 | ||
| Fwd PE | 14.56 | ||
| P/S | 4.93 | ||
| P/FCF | 14.35 | ||
| P/OCF | 13.88 | ||
| P/B | 3.02 | ||
| P/tB | 5.69 | ||
| EV/EBITDA | 10.67 |
EPS(TTM)1.02
EY4.98%
EPS(NY)1.41
Fwd EY6.87%
FCF(TTM)1.43
FCFY6.97%
OCF(TTM)1.48
OCFY7.21%
SpS4.16
BVpS6.79
TBVpS3.61
PEG (NY)0.66
PEG (5Y)0.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.25% | ||
| ROE | 17.77% | ||
| ROCE | 17.53% | ||
| ROIC | 13.65% | ||
| ROICexc | 25.24% | ||
| ROICexgc | 117.06% | ||
| OM | 31.65% | ||
| PM (TTM) | 29.01% | ||
| GM | 96.83% | ||
| FCFM | 34.35% |
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
ROICexc(3y)77.56%
ROICexc(5y)85.03%
ROICexgc(3y)80.41%
ROICexgc(5y)91.41%
ROCE(3y)17.1%
ROCE(5y)20.32%
ROICexcg growth 3Y-13.79%
ROICexcg growth 5Y3.99%
ROICexc growth 3Y-11.73%
ROICexc growth 5Y9.55%
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.16 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.58% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | 200.13 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 118.41% | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 5.02 | ||
| Altman-Z | 9.53 |
F-Score5
WACC6.68%
ROIC/WACC2.04
Cap/Depr(3y)105.55%
Cap/Depr(5y)103.01%
Cap/Sales(3y)2.49%
Cap/Sales(5y)2.51%
Profit Quality(3y)97.9%
Profit Quality(5y)95.71%
High Growth Momentum
Growth
EPS 1Y (TTM)9.53%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS Q2Q%-38.72%
EPS Next Y30.57%
EPS Next 2Y22.38%
EPS Next 3Y23.55%
EPS Next 5Y23.29%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Sales Q2Q%16.78%
Revenue Next Year28.56%
Revenue Next 2Y22.38%
Revenue Next 3Y19.9%
Revenue Next 5Y17.88%
EBIT growth 1Y-8.06%
EBIT growth 3Y-5.54%
EBIT growth 5Y30.98%
EBIT Next Year23.79%
EBIT Next 3Y22.85%
EBIT Next 5Y24.51%
FCF growth 1Y231.72%
FCF growth 3Y4.57%
FCF growth 5Y67.11%
OCF growth 1Y201.48%
OCF growth 3Y4.68%
OCF growth 5Y48.71%